Periodic Reporting for period 1 - pBioStrat-for-PDA (Use of PAP as a biomarker and stratifier of pancreatic cancer to improve patient management)
Berichtszeitraum: 2018-09-01 bis 2020-02-29
With respect to numerous biomarkers under development, pBioStrat-for-PDA wanted to provide a powerful tool for clinicians in order to better determine the resectability of a tumor by taking into account its biological nature. Indeed, our preliminary study revealed that high level of PAP/REG3A is observed for patients with PDA of higher grade, with reduced global and disease-free survival, even though those patients were eligible for surgery. At present, no biomarker intending to improve the prediction of resectability are under investigation. As a consequence the use of a non-invasive PAP/REG3A serum level determination will improve patients’ managements by (1) shortening the delay to start palliative chemotherapy, (2) limiting unnecessary surgery with important mortality/morbidity and (3) improving their redirection to adapted clinical trials, as the one targeting JAK2/STAT3 signalling.
While still of interest and representating a real need from the cinicians, this project was not achieved due to limitation in cohort implementation for several technical, societal and financial reasons. unfortunatly, only 250 samples were collected and the cohort is still under implementation.
Regarding those issues the socioeconomical impact could not be evaluated.